golimumab

A human monoclonal antibody directed against the pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-a) with immunosuppressive activity… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Recent insights in rheumatoid arthritis (RA) necessitated updating the European League Against Rheumatism (EULAR) RA management… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND & AIMS Little is known about the efficacy of golimumab, a fully human monoclonal antibody to tumor necrosis factor… (More)
  • table 1
  • table 1
  • table 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND & AIMS Subcutaneous golimumab, a fully human monoclonal antibody to tumor necrosis factor-α (TNFα), was evaluated as… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • table 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
OBJECTIVE Golimumab, administered subcutaneously every 4 weeks, has been shown to be effective in reducing the signs and symptoms… (More)
  • table 1
  • figure 1
  • table 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2010
Highly Cited
2010
OBJECTIVE To evaluate the efficacy and safety of golimumab to 52 weeks in patients with active rheumatoid arthritis despite… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BACKGROUND Tumour necrosis factor alpha (TNFalpha) inhibitors are frequently used to treat rheumatoid arthritis, but whether use… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
OBJECTIVE The phase III GO-FORWARD study examined the efficacy and safety of golimumab in patients with active rheumatoid… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
OBJECTIVE To assess the safety and efficacy of golimumab in methotrexate (MTX)-naive patients with active rheumatoid arthritis… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
RATIONALE The treatment effect of golimumab, a human monoclonal antibody against tumor necrosis factor (TNF)-alpha, in severe… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
OBJECTIVE To assess the efficacy, safety, and pharmacology of subcutaneous administration of golimumab in patients with active… (More)
Is this relevant?